The COVID-19 pandemic has resulted in new challenges in lung clinical trials, such as patients being unable to access hospital spirometry.
A recent study reported by Khan et al. investigated the potential of using home spirometry as a clinical endpoint in fibrotic ILD. The study concluded that “Home spirometry in fibrotic ILD is feasible and non-inferior to hospital spirometry.” Read the full report by Khan et al.
Learn how Vitalograph’s custom solutions and personalised approach meet a wide range of respiratory clinical study needs, including home spirometry.